Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-01-09
2007-01-09
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S235100, C435S325000
Reexamination Certificate
active
10736640
ABSTRACT:
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.
REFERENCES:
patent: 4716104 (1987-12-01), Harris et al.
patent: 4762780 (1988-08-01), Spector et al.
patent: 5635363 (1997-06-01), Altman et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 6074645 (2000-06-01), Diamond et al.
patent: WO 94/00150 (1994-01-01), None
patent: WO 97/40165 (1997-10-01), None
patent: WO 98/26074 (1998-06-01), None
patent: WO 99/19349 (1999-04-01), None
patent: WO 00/75180 (2000-12-01), None
Alexander et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides,”Immunity1:751-761, Dec. 1994.
Bernhard et al., “Cytotoxic T Lymphocytes from HLA-A2 Transgenic Mice Specific for HLA-A2 Expressed on Human Cells,”J. Exp. Med. 168:1157-1162, Sep. 1988.
Berzofsky et al., “Construction of peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce in Vitro T Cell Responses in Mice and Humans of Multiple MHC Types,”The J. of Clinical Investigation88:876-884, Sep. 1991.
Boppana et al., “Recognition of Human Cytomegalovirus Gene Products by HCMV-specific Cytotoxic T Cells,”Virology222:293-296, 1996.
Borysiewicz et al., “Relative Frequency of Stage-specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses,”J. Exp. Med. 168:919-931, Sep. 1988.
Brouwenstijn et al., “Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma,”J. of Immunotherapy21 (6):427-434, 1998.
Chujoh et al., “The role of anchor residues in the binding of peptides to HLA-A*1101 molecules,”Tissue Antigens52:501-509, 1998.
Clay et al., “Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue,”J. of Immunology162:1749-1755, 1999.
Greenberg et al. “Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantatoin recipients by adoptive transfer of donor-derived CMV-specific T cell clones expandedin vitro” in:Annals of the New York Academy of Sciences(Antigen and Clone-Specific Immunoregulation) 636:184-195, 1991.
Gyulai et al., “Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healty Individuals: Reevaluation of Prevalence of IE1-Specific CTLs,”The J. of Infectious Diseases181:1537-46, 2000.
Ishioka et al. “Utilization of MHC Class I transgenic mice for development of minigen DNA vaccines encoding multiple HLA-restricted CTL epitopes,”J. Immunology162:3915-3925, 1999.
Kern et al., “Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides,”Eur. J. Immunol. 30:1676-1682, 2000.
Kern et al., “Target Structures of the CD8+-T Cell Response to Human Cytomegalovirus: the 72 Kilodalton Major Immediate-Early Protein Revisited,”J. of Virology73(10):8179-8184, Oct. 1999.
Lipford et al. “Peptide Engineering Allows Cytotoxic T-cell Vaccination Against Human Papilloma Virus Tumour Antigen, E6,”Immunology84:298-303, 1995.
Livingston et al. “Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans,”J. Immunology162:3088-3095, 1999.
Ohlin et al., “Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus,”Clin. Exp. Immunol. 84:508-514, 1991.
Oseroff et al. “Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL eiptope responses,”Vaccine16(8):823-833, 1998.
Panina-Bordignon et al., “Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells,”Eur. J. Immunol. 19:2237-2242, 1989.
Retiére et al., “Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response,”J. of Virology74(9):3948-3952, May 2000.
Riddell et al., “Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression,”J. Immunology146(8):2795-2804, Apr. 15, 1991.
Rüger, et al. “Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus,”J. Virology61(2):446-453 Feb. 1987.
Schild et al., “Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells,”Eur. J. Immunol. 21:2649-2654, 1991.
Theobald et al., “Targeting p53 as a general tumor antigen,”Proc. Natl. Acad. Sci. USA92:11993-11997, Dec. 1995.
Tsunoda et al. “Lipopeptide particles as the immunologically active component of CTL inducing vaccines,”Vaccine17:675-685, 1999.
Vierboom et al. “Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-Induced Tumors Expressing the Wild-Type Epitope,”J. Immunotherapy21(6):399-408, 1998.
Wentworth et al., “Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice,”Eur. J. Immunol. 26:97-101, 1996.
Wentworth et al. “In Vitroinduction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides,”Molecular Immunology32(9):603-612, 1995.
Moldoveanu, Zina, et al., “CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus,”Vaccine16(11/12):1216-1224, 1998.
Vitiello et al., “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection,”J. Clin. Invest., 95:341-349, 1995.
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science, 274:94-96, 1996.
Crawford et al.,“Detection of Antigen-Specific T Cells with Multivalent Soluble Class II MHC Covalent Peptide Complexes,”Immun., 8:675-682, 1998.
Liu et al., “Detection of glutamic acid decarboxylase-activated T cells with I-Ag7tetramers,”PNAS Early Edition, 1-6 (www.pnas.org) Oct. 16, 2000.
Gillespie et al., “Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors,”Journal of Virology74(17):8140-8150, 2000.
Appay et al., “HIV-specific CD8+T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function,”.J. Exp. Med., 192:1, 63-75, 2000.
Shacklett et al., “Isolation of Cytomegalovirus-Specific Cytotoid T-Lymphocytes from Gut-Associated Lymphoid Tissue (GALT) of HIV Type 1-Infected Subjects”,Aids Research and Human Retroviruses, 16:12, 1157-1162, 2000.
“Use Of A CMV pp65-Specific HLA Tetramer to Select and Expand CMV-Specific CD8+ CTL,”The Journal of the American Society of Hematology94:10, 155a, Nov. 15, 1999 (Abstract).
Zala et al., “Status of Cytomegalovirus Prevention and Treatment in 2000,”American Society of Hematology339
City of Hope
Rothwell Figg Ernst & Manbeck P.C.
Salimi Ali R.
LandOfFree
Diagnostic reagents for human cytomegalovirus and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic reagents for human cytomegalovirus and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic reagents for human cytomegalovirus and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753335